The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: A meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 4, 2012, Pages 555-561

  Cai, Xu ^a   Yang, Ming ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

MDM2; Osteosarcoma; P53; Sarcoma; Single nucleotide polymorphism

Indexed keywords

ARGININE; GLYCINE; PROLINE; PROTEIN MDM2; PROTEIN P53; THREONINE;

ARTICLE; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MOLECULAR EPIDEMIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

AMINO ACID SUBSTITUTION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863093198     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1124-8     Document Type: Article

References (53)

1. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin JP, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T-[G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694-698 (Pubitemid 41306059)
2. Almeida PS, Manoel WJ, Reis AA, Silva ER, Martins E, Paiva MV, Fraga AC Jr, Saddi VA (2008) TP53 codon 72 polymorphism in adult soft tissue sarcomas. Genet Mol Res 7:1344-1352
3. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J (2005) A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280:26776-26787 (Pubitemid 41040711)
4. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468 (Pubitemid 23073692)
5. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133-1141 (Pubitemid 44470358)
6. Bhagwat GP, Naik KG, Sachdeva R, Bhushan V (1980) Disseminated lymphadenopathic Kaposi's sarcoma in Zambian children. Med J Zambia 14:61-63 (Pubitemid 13095286)
7. Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26:1317-1323 (Pubitemid 46328460)
8. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602 (Pubitemid 39535748)
9. Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65:5481-5484 (Pubitemid 40911143)
10. Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G (1996) Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 65:25-28 (Pubitemid 26027535)
11. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869
12. Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445-2452 (Pubitemid 26123766)
13. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8:25-37
14. Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701-711 (Pubitemid 41175678)
15. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365 (Pubitemid 36278852)
16. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634 (Pubitemid 27387172)
17. Eymin B, Gazzeri S, Brambilla C, Brambilla E (2002) Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 21:2750-2761 (Pubitemid 34478333)
18. Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994) MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86:1297-1302 (Pubitemid 24276791)
19. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402:889-894
20. Gallo RC (1998) The enigmas of Kaposi's sarcoma. Science 282:1837-1839 (Pubitemid 28555252)
21. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299 (Pubitemid 27220766)
22. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65:9582-9587 (Pubitemid 41508029)
23. HuGELiterature Finder (2011). http://hugenavigator.net/HuGENavigator/ startPagePubLit.do
24. Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, Zumstein-Mecker S, Choong PF, Dickinson I, Crowe P, Hemmings C, Desai J, Thomas DM, Lisztwan J (2011) Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 17:416-426
25. Kotilingam D, Lev DC, Lazar AJ, Pollock RE (2006) Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin 56:282-291 quiz 314-315 (Pubitemid 44527490)
26. Landers JE, Cassel SL, George DL (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57:3562-3568 (Pubitemid 27355508)
27. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234 (Pubitemid 23156805)
28. Lee HR, Toth Z, Shin YC, Lee JS, Chang H, Gu W, Oh TK, Kim MH, Jung JU (2009) Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol 83:6739-6747
29. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238 (Pubitemid 120031831)
30. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
31. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9:714-723
32. Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531-1543
33. Oettle AG (1962) Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum 18:330-363
34. Ørsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG (2007) Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 204:1295-1301 (Pubitemid 46919867)
35. Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3-13
36. Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P (2010) Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 22:64-69
37. Petitti DB (1994) Of babies and bathwater. Am J Epidemiol 140:779-782
38. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C, Osman I (2001) HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61:7642-7646 (Pubitemid 32995060)
39. Rayburn E, Zhang R, He J, Wang H (2005) MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27-41 (Pubitemid 40321798)
40. Savage SA, Burdett L, Troisi R, Douglass C, Hoover RN, Chanock SJ, National Osteosarcoma Etiology study group (2007) Germline genetic variation of TP53 in osteosarcoma. Pediatr Blood Cancer 49:28-33 (Pubitemid 46850651)
41. Si H, Robertson ES (2006) Kaposi's sarcoma-associated herpesvirusencoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol 80:697-709 (Pubitemid 43062883)
42. Siddique M, Sabapathy K (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25:3489-3500 (Pubitemid 43901670)
43. Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaufox MD (1969) Disseminated visceral Kaposi's sarcoma. Appearance after human renal homograft operation. JAMA 207:1493-1496
44. Slavin G, Cameron HM, Forbes C, Mitchell RM (1970) Kaposi's sarcoma in East African children: a report of 51 cases. J Pathol 100:187-199
45. Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M (2009) Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 15:3550-3556
46. Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Katongole-Mbidde E, Buonaguro L, Buonaguro FM (2009) TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology 77:328-334
47. Tornesello ML, Buonaguro L, Cristillo M, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Viviano E, Romano N, Katongole-Mbidde E, Buonaguro FM (2011) MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers 16:42-50
48. US National Library of Medicine, National Institutes of Health (2011) PubMed home page. http://preview.ncbi.nlm.nih.gov/pubmed
49. Vesely K, Jurajda M, Nenutil R, Vesela M (2009) Expression of p53, cyclin D1 and EGFR correlates with histological grade of adult soft tissue sarcomas: a study on tissue microarrays. Neoplasma 56:239-244
50. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310
51. Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL (1999) Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 18:783-788 (Pubitemid 29080336)
52. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D (2007) Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28:1996-2001 (Pubitemid 47500614)
53. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ (2008) A navigator for human genome epidemiology. Nat Genet 40:124-125